自体外周血干细胞移植治疗血液肿瘤206例观察

目的:观察自体外周血干细胞移植(APBSCT)治疗血液恶性肿瘤临床疗效。方法:自2001年3月—2006年12月对206例血液肿瘤患者施行APBSCT,其中急性淋巴细胞白血病(ALL)40例,急性髓细胞白血病(AML)29例,非何杰金淋巴瘤(NHL)95例,何杰金淋巴瘤(HD)26例,多发性骨髓瘤(MM)16例,观察临床疗效和并发症。结果:除1例ALL外,205例患者移植后造血功能均快速重建。急性淋巴细胞白血病首次完全缓解(ALL-CR1)25例,其中无病存活17例,带病存活2例,死亡6例,急性淋巴细胞白血病再次完全缓解(ALL-CR2)15例,其中无病存活3例,带病存活3例,死亡9例;急性髓细胞白血病首次完全缓解(AML-CR1)17,其中无病存活10例,带病存活2例,死亡5例,急性髓细胞白血病再次完全缓解(AML-CR2)12例,其中无病存活5例,带病存活1例,死亡6例;非何杰金淋巴瘤首次缓解(NHL-CR1)57例,其中无病存活42例,带病存活6例,死亡9例,非何杰金淋巴瘤再次缓解(NHL-CR2)28例,其中无病存活18例,带病存活4例,死亡6例,非何杰金淋巴瘤未缓解(NHL-NR)10例,其中无病存活2例,带病存活3例,死亡5例;何杰金淋巴瘤首次缓解(HD-CR1)8例,其中无病存活8例;何杰金淋巴瘤部分缓解(HD-PR)13例,其中无病存活11例,带病存活2例;RE5例,其中无病存活3例,带病存活1例,死亡1例;MM16例,其中无病存活5例,带病存活4例,死亡7例。结论:APBSCT是一种治疗血液肿瘤安全有效的方法。

Clinical Analysis on Autologous Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in 206 Cases

Objective:To evaluate clinical effect of autologous peripheral blood stem cell transplantation (APBSCT) on the treatment of hematologic malignancies.Methods:Two hundreds and six patients (ALL in 40 cases, AML in 29 cases, NHL in 95 cases,HD in 26 cases,MM in 16 cases)with hematologic malignancies received APBSCT from May 2001 to December 2006.Therapeutic effect and complication was oberserved. Results: Two hundreds and five patients obtained hematopoieteic reconstitution quickly,while one case failed. ALL-CR1 The first time CR of were 17 in disease free survival(DFS), 2 in live with disease(LWD) and 6 in death; the second time CR ALL-CR2 were 3 in DFS, 3 in LWD and 9 in death; AML-CR1 were 10 in DFS, 2 in LWD, 5 in death; AML-CR2 were 5 in DFS, 1 in LWD, 6 in death;NHL-CR were 42 in DFS, 6 in LWD, 9 in death;NHL-CR2 were 18 in DFS, 4 in LWD, 6 in death;NHL-NR were 2 in DFS, 3 in LWD, 5 in death;HD-CR1 were 8 in DFS;HD-PR were 8 in DFS, 2 in LWD;HD-RE were 3 in DFS, 1 in LWD, 1 in death;MM were 5 in DFS, 4 in LWD, 7 in death.Conclusion:APBSCT is a safe and effective therapy method treated for hematologic malignancies.